HCV

BOSTON, July 28, 2026 Atea Pharmaceuticals announced positive topline results from its pivotal Phase 3 C-BEYOND trial, with its...

NORTH CHICAGO, Ill., June 23, 2026 AbbVie announced that the European Commission has approved MAVIRET® (glecaprevir/pibrentasvir) for the treatment...

North Chicago, Illinois, USA – May 22, 2026 AbbVie announced that the European Medicines Agency’s Committee for Medicinal Products...